1. Home
  2. WVE vs WLYB Comparison

WVE vs WLYB Comparison

Compare WVE & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • WLYB
  • Stock Information
  • Founded
  • WVE 2012
  • WLYB 1807
  • Country
  • WVE Singapore
  • WLYB United States
  • Employees
  • WVE N/A
  • WLYB N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • WLYB Books
  • Sector
  • WVE Health Care
  • WLYB Consumer Discretionary
  • Exchange
  • WVE Nasdaq
  • WLYB Nasdaq
  • Market Cap
  • WVE 939.3M
  • WLYB 2.3B
  • IPO Year
  • WVE 2015
  • WLYB N/A
  • Fundamental
  • Price
  • WVE $6.54
  • WLYB $44.00
  • Analyst Decision
  • WVE Strong Buy
  • WLYB
  • Analyst Count
  • WVE 11
  • WLYB 0
  • Target Price
  • WVE $20.91
  • WLYB N/A
  • AVG Volume (30 Days)
  • WVE 1.7M
  • WLYB 807.0
  • Earning Date
  • WVE 05-08-2025
  • WLYB 06-12-2025
  • Dividend Yield
  • WVE N/A
  • WLYB 3.21%
  • EPS Growth
  • WVE N/A
  • WLYB N/A
  • EPS
  • WVE N/A
  • WLYB 0.75
  • Revenue
  • WVE $104,939,000.00
  • WLYB $1,703,491,000.00
  • Revenue This Year
  • WVE N/A
  • WLYB N/A
  • Revenue Next Year
  • WVE N/A
  • WLYB $1.13
  • P/E Ratio
  • WVE N/A
  • WLYB $57.97
  • Revenue Growth
  • WVE N/A
  • WLYB N/A
  • 52 Week Low
  • WVE $4.25
  • WLYB $35.68
  • 52 Week High
  • WVE $16.74
  • WLYB $52.90
  • Technical
  • Relative Strength Index (RSI)
  • WVE 42.23
  • WLYB 65.28
  • Support Level
  • WVE $6.30
  • WLYB $39.54
  • Resistance Level
  • WVE $8.39
  • WLYB $44.15
  • Average True Range (ATR)
  • WVE 0.66
  • WLYB 0.01
  • MACD
  • WVE 0.10
  • WLYB 0.12
  • Stochastic Oscillator
  • WVE 33.21
  • WLYB 86.96

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

Share on Social Networks: